INFORME DE BÚSQUEDA DE PATENTES	
N° de solicitud: 14000880	
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados)**	
Palabras clave utilizadas	PHARMACEUTICAL COMPOSITION; AMIDE DERIVATIVE; INHIBITING THE GROWTH OF CANCER CELLS; NON-METALLIC SALT LUBRICANT; SUCROSE FATTY ACID ESTERS,
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA	**CIP:** A01N 25/16.
	CPC (Opcional):

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc…)

Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
ORBIT, EPOQUENET, ESPACENET, USPTO	US2010179120	15/Julio/2010	1 a 10 NIVEL INVENTIVO	Y
	WO2005105050	10/Noviembre/2005	1 a 10 NIVEL INVENTIVO	Y

** Categorías especiales de documentos citados:

"A" documento que define el estado general de la técnica no considerado como particularmente relevante. **"E"** solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. **"P"** documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.	**"X"** documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. **"Y"** documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	
Fecha del reporte de búsqueda:	06/06/2018

ESPACENET

Documents cited:	**Search**	[Y] WO2008150118 (HANMI PHARM IND CO LTD [KR], et al) [Y] 1-16 * page 88; example 36 * * Preparation example 1; pages 102-103 *;
		[AP] WO2011155793 (HANMI HOLDINGS CO LTD [KR], et al) [AP] 1-16 * the whole document *
		[Y] - Anonymous, Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (2006), XP002736604 [Y] 1-16 * page 767 *
		[Y] - Anonymous, The Merck Index, Merck&Co., Inc., (2001), XP002736605 [Y] 1-16 * item 5675; page 5682 *
	International search	[A] KR101013319B (HANMI PHARM. CO., LTD.);
		[A] KR20050104152 (CHOI SEUNG HO [KR])

USPTO



ORBIT



EPOQUENET

New connection on: : 20-07-2018 : 00:55:28 - Last disconnection on: : 19-07-2018 : 22:12:43

V 4.0.0.44358(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201802)) (RPM D201802)

Welcome to EPOQUE Rebuild under the Production Environment

[EPODOC: SS 1] ..FI

Select a database: ..FI EPODOC

Database: EPODOC

[EPODOC: SS 1] SUCROSE AND FATTY AND ACID AND ESTERS

Results in EPODOC **686**

[SS 2] NON-METALLIC AND SALT AND LUBRICANT

Results in EPODOC **0**

EPODOC: term 'NON-METALLIC' not found in index 'BI'. *WARNING(1)*

[SS 3] NON AND METALLIC AND SALT AND LUBRICANT

Results in EPODOC **52**

[SS 4] 3 AND 1

Results in EPODOC **0**

[SS 5] 1 AND POORLY AND ABSORBED

Results in EPODOC **5**

[SS 6] ..li pn ti ab

1/5 © EPODOC / EPO

PN - US2013171248 A1 20130704

TI - ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED** DRUGS

AB - A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

2/5 © EPODOC / EPO

PN - US2011045029 A1 20110224

TI - ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED** DRUGS

AB - A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

3/5 © EPODOC / EPO

PN - WO2005105050 A1 20051110

TI - ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED** DRUGS

AB - A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly (amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

4/5	© EPODOC / EPO
PN	- US2006088592 A1 20060427
TI	- (A1 B2) Oral formulation for delivery of **poorly absorbed** drugs
AB	- (A1 B2) A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly (amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

5/5	© EPODOC / EPO
PN	- MXPA06012489 A 20070208
TI	- ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED** DRUGS.
AB	- A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly (amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).